We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compandia Appoints Dr Dave Tapolcazy as new Non Executive Chairman
News

Compandia Appoints Dr Dave Tapolcazy as new Non Executive Chairman

Compandia Appoints Dr Dave Tapolcazy as new Non Executive Chairman
News

Compandia Appoints Dr Dave Tapolcazy as new Non Executive Chairman

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Compandia Appoints Dr Dave Tapolcazy as new Non Executive Chairman"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compandia announces the appointment of its new non exec chairman Dr Dave Tapolczay. Dave is CEO of Medical Research Council Technology, the commercialization company for the MRC.

Compandia CEO, Andy Sutton announced, “We are thrilled that Dave has joined Compandia and will bring significant experience from his years at GSK, Millenium, Pharmorphix and AZ. Dave will add a strategic view from both the large International Corporate and Start Up perspectives and bring a wealth of knowledge regarding current trends affecting the Pharma and Biotech Sectors which will assist Compandia in positioning its services for optimal delivery”.

Compandia is a biomarker discovery and bioinformatics spin out from Nottingham Trent University. Compandia uses advanced bioinformatics tools to derive biomarker panels from complex biological data being generated in the Pharmaceutical, Biotech and Biomedical sectors.

Compandia claims that it’s advantage is the ability to find small biomarker panels from data that would otherwise be impossible to decipher this enables disease states to be accurately diagnosed from a small number of analytes.

Compandia in addition offers proteomic services coupled to its “Biomarker Distiller” for the discovery of proteomic biomarker panels.

Compandia also announced the launch of a new bioinformatics capability, its “Pathways Distiller” bioinformatics tool that creates maps of interacting gene pathways which define patient populations such as drug responders from non responders.
Advertisement